Post by CorWave

CorWave LVAS is a “quantum leap” in heart pump technology.   We would like to thank Dr. Paul Jansz, who yesterday delivered the first-ever surgical presentation of the CorWave LVAS at the Techno-College during the 39th Annual Meeting of the EACTS - European Association for Cardio-Thoracic Surgery in Copenhagen.   Before an international audience of several hundred cardiothoracic surgeons, Dr. Jansz shared insights from the First-in-Human implantation of our heart pump, which he led at St Vincent's Health Australia, highlighting key clinical outcomes:   🔹 A standardized and streamlined surgical approach grounded in experience from thousands of LVAD implantations 🔹 No device-related serious adverse events 🔹 Pulsatility preserved throughout the study, with beat-to-beat valve opening 🔹 Successful transplantation after 84 days of support and no thrombus observed at explant   🎙️ “𝘐 𝘵𝘩𝘪𝘯𝘬 𝘵𝘩𝘪𝘴 𝘪𝘴 𝘢 𝘲𝘶𝘢𝘯𝘵𝘶𝘮 𝘭𝘦𝘢𝘱 𝘪𝘯 𝘵𝘦𝘳𝘮𝘴 𝘰𝘧 𝘥𝘦𝘷𝘪𝘤𝘦𝘴. 𝘞𝘦'𝘷𝘦 𝘨𝘰𝘵 𝘧𝘶𝘭𝘭 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘢𝘯𝘥 𝘱𝘶𝘭𝘴𝘢𝘵𝘪𝘭𝘦 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘵𝘩𝘢𝘵 𝘐 𝘩𝘢𝘷𝘦𝘯'𝘵 𝘴𝘦𝘦𝘯 𝘣𝘦𝘧𝘰𝘳𝘦”, he concluded. [𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.] #EACTS2025 #innovation #medtech #LVAS #CardiothoracicSurgery #heartfailure